FAIR LAWN, N.J.--(BUSINESS WIRE)--Citing a significant advance in drug delivery, Vyteris, Inc. (OTC BB: VYHN) and Ferring Pharmaceuticals today announced results from a completed Phase 1 clinical trial demonstrating that Vyteris’ patented Smart Patch transdermal technology successfully delivered a peptide molecule in humans (multiple pulse) without the use of needles (non invasively) in therapeutic levels aimed at the treatment of female infertility.
